Related Experiment Video
Updated: Dec 27, 2025

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Long-Term Outcomes of Anticoagulation for Bioprosthetic Valve Thrombosis
Ioana Petrescu1, Alexander C Egbe2, Filip Ionescu1
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; Department of Internal Medicine, Beaumont Health System, Royal Oak, Michigan.
Insights
Anticoagulation effectively treats bioprosthetic valve thrombosis (BPVT), but long-term outcomes show increased bleeding and re-BPVT risk. Patients with BPVT experienced higher rates of valve re-replacement, necessitating careful consideration of indefinite anticoagulation.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Medical Outcomes Research
Background:
- Bioprosthetic valve thrombosis (BPVT) is a rare but serious complication after heart valve replacement.
- While anticoagulation is effective for acute BPVT, long-term outcomes and risks remain incompletely understood.
Purpose of the Study:
- To evaluate the long-term clinical outcomes of patients diagnosed with bioprosthetic valve thrombosis (BPVT).
- To assess the efficacy and safety of anticoagulation therapy in managing BPVT and its sequelae.
Main Methods:
- A matched cohort study comparing 83 patients with BPVT treated with warfarin to 166 control subjects.
- Matching criteria included age, sex, implantation year, and prosthesis type/position.
- Median follow-up was 34 months.
Main Results:
- Echocardiographic normalization occurred in 75% of BPVT patients within 3 months; 25% did not respond to warfarin.
- No significant difference in the primary composite endpoint between BPVT patients and controls.
- BPVT patients had a higher rate of major bleeding (12% vs. 2%) and valve re-replacement (68% vs. 24% at 10 years).
- Recurrent BPVT (re-BPVT) occurred in 23% of responders, with most responding to further anticoagulation.
Conclusions:
- Bioprosthetic valve thrombosis is associated with recurrent thrombosis and early prosthetic degeneration.
- Indefinite warfarin anticoagulation may be considered for confirmed BPVT, balancing efficacy against increased bleeding risk.
- Long-term monitoring and management strategies are crucial for patients with BPVT.
Background:
Early in the prevention and treatment of bioprosthetic valve thrombosis (BPVT), anticoagulation is effective, but the long-term outcome after BPVT is unknown.
Objectives:
The goal of this study was to assess the long-term outcomes of patients with BPVT treated with anticoagulation.
Methods:
This analysis was a matched cohort study of patients treated with warfarin for suspected BPVT at the Mayo Clinic between 1999 and 2017.
Results:
A total of 83 patients treated with warfarin for suspected BPVT (age 57 ± 18 years; 45 men [54%]) were matched to 166 control subjects; matching was performed according to age, sex, year of implantation, and prosthesis type and position. Echocardiography normalized in 62 patients (75%) within 3 months (interquartile range [IQR]: 1.5 to 6 months) of anticoagulation; 21 patients (25%) did not respond to warfarin. Median follow-up after diagnosis was 34 months (IQR: 17 to 54 months). There was no difference in the primary composite endpoint between the patients with BPVT and the matched control subjects (log-rank test, p = 0.79), but the former did have a significantly higher rate of major bleeding (12% vs. 2%; p < 0.0001). BPVT recurred (re-BPVT) in 14 (23%) responders after a median of 23 months (IQR: 11 to 39 months); all but one re-BPVT patient responded to anticoagulant therapy. Patients with BPVT had a higher probability of valve re-replacement (68% vs. 24% at 10 years' post-BPVT; log-rank test, p < 0.001).
Conclusions:
BPVT was associated with re-BPVT and early prosthetic degeneration in a significant number of patients. Indefinite warfarin anticoagulation should be considered after a confirmed BPVT episode, but this strategy must be balanced against an increased risk of bleeding.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Endocarditis III: Medical Management
Mitral Stenosis III: Medical Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Peripheral Artery Disease V: Postoperative Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

